Treatment of blastic plasmacytoid dendritic cell neoplasm
- 2 December 2016
- journal article
- research article
- Published by American Society of Hematology in Hematology
- Vol. 2016 (1), 16-23
- https://doi.org/10.1182/asheducation-2016.1.16
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy with no defined standard of care. BPDCN presents most commonly with skin lesions with or without extramedullary organ involvement before leukemic dissemination. As a result of its clinical ambiguity, differentiating BPDCN from benign skin lesions or those of acute myeloid leukemia with leukemia cutis is challenging. BPDCN is most easily defined by the phenotype CD4+CD56+CD123+lineage–MPO–, although many patients will present with variable expression of CD4, CD56, or alternate plasmacytoid markers, which compounds the difficulty in differentiating BPDCN from other myeloid or lymphoid malignancies. Chromosomal aberrations are frequent, and the mutational landscape of BPDCN is being rapidly characterized although no obvious molecular target for chemoimmunotherapy has been identified. Chemotherapy regimens developed for acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome have all been used to treat BPDCN. Relapse is frequent, and overall survival is quite poor. Allogeneic transplantation offers a chance at prolonged remission and possible cure for those who are eligible; unfortunately, relapse remains high ranging from 30% to 40%. Novel therapies such as SL-401, a diphtheria toxin conjugated to interleukin-3 (IL-3) is commonly overexpressed in BPDCN and other aggressive myeloid malignancies and has shown considerable promise in ongoing clinical trials. Future work with SL-401 will define its place in treating relapsed or refractory disease as well as its role as a first-line therapy or bridge to transplantation.This publication has 62 references indexed in Scilit:
- Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow TransplantationBlood, 2013
- Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasmBone Marrow Transplantation, 2012
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter studyHaematologica, 2012
- Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following TransplantCase Reports in Transplantation, 2011
- Cutaneous Manifestations of Blastic Plasmacytoid Dendritic Cell Neoplasm—Morphologic and Phenotypic Variability in a Series of 33 PatientsThe American Journal of Surgical Pathology, 2010
- Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the diseaseLeukemia, 2009
- Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasmHaematologica, 2008
- CD4‐negative variant of CD4+/CD56+ hematodermic neoplasm: description of three casesJournal of Cutaneous Pathology, 2008
- Novel markers of normal and neoplastic human plasmacytoid dendritic cellsBlood, 2008
- The role of interleukin-3 in classical Hodgkin's diseaseLeukemia & Lymphoma, 2005